Drug intelligence / Profile preview

Huizhisu

Development stage: Unknown
Lead developer: Hainan Huizhikang Medical Research
Modality: Small Molecules
Administration: Oral

Overview

Huizhisu is a multi-ingredient functional food derived from natural plant extracts, including rice bran, soybean, and Angelica dahurica. It is being investigated for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and Autistic Spectrum Disorder (ASD). Its proposed mechanisms of action include acetylcholinesterase inhibition, antioxidant and anti-inflammatory effects, inhibition of amyloid-beta aggregation, and modulation of serotonin receptors. The product is developed by Japan Glovia Co., Ltd. and is undergoing clinical trials, including a randomized, double-blind, multi-center, placebo-controlled trial for ADHD.

Brand names: Huizhisu
Other names: 慧之素

Targets

5-HT (Serotonin receptors)AcetylcholinesteraseAβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on Huizhisu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huizhisu.

Explore the full profile